<code id='6D31393203'></code><style id='6D31393203'></style>
    • <acronym id='6D31393203'></acronym>
      <center id='6D31393203'><center id='6D31393203'><tfoot id='6D31393203'></tfoot></center><abbr id='6D31393203'><dir id='6D31393203'><tfoot id='6D31393203'></tfoot><noframes id='6D31393203'>

    • <optgroup id='6D31393203'><strike id='6D31393203'><sup id='6D31393203'></sup></strike><code id='6D31393203'></code></optgroup>
        1. <b id='6D31393203'><label id='6D31393203'><select id='6D31393203'><dt id='6D31393203'><span id='6D31393203'></span></dt></select></label></b><u id='6D31393203'></u>
          <i id='6D31393203'><strike id='6D31393203'><tt id='6D31393203'><pre id='6D31393203'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:1941
          Exterior photo of UnitedHealth Group building
          Courtesy UnitedHealth Group

          UnitedHealth Group has about 90,000 employed or affiliated doctors, approximately 10% of all physicians in the U.S.

          The number — disclosed Wednesday at the company’s investor day by Amar Desai, the CEO of UnitedHealth’s Optum Health division — means the company acquired or hired 20,000 doctors in the past year alone.

          advertisement

          The rapid growth of UnitedHealth’s physician base underscores how the company, which already is the country’s largest private health insurer, is looking to control more of the health care delivery system, and how this growth is going unchecked by antitrust agencies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Vivek Ramaswamy made waves in the debate, much as in biotech
          Vivek Ramaswamy made waves in the debate, much as in biotech

          BusinessmanVivekRamaswamyandformerU.N.AmbassadorNikkiHaleyAPPhoto/MorryGashTheyoungestcandidateonWed

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear